As Gilead Sciences Inc. continues its march into oncology with the aim of diversifying outside of infectious disease, the company announced Dec. 12 that it will acquire the Canadian cancer company YM BioSciences Inc.
The price is $2.95 per share in cash, or about $510 million, with the transaction expected to close in the first quarter